Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A.

"Conflict of Interest O.V. has received speakers fees from Novo Nordisk and received research support from Bayer. M.H.C. has received investigator-initiated research grants over the years from the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch “Innovatiefonds Zorgverzekeraars,” Baxter/Baxalta/Shire, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi, Biogen, Novo Nordisk, Novartis, and Nordic Pharma, and has served as a steering board member for Roche and Bayer. All grants, awards, and fees go to the Erasmus MC as institution. M.O.K. received grants from Bayer, Roche, and Merck. R.A.A.M. reports grants from Bayer, grants from Shire, grants from Merck Sharpe Dome, grants from CSL Behring, other from Bayer, other from Shire, outside the submitted work. K.F. has received speaker's fees from Bayer, Baxter/Shire, Sobi/Biogen, CSL Behring, Octapharma, Pfizer, and Novo Nordisk, and has performed consultancy for Bayer, Baxter, Biogen, CSL Behring, Freeline, Novo Nordisk, Pfizer, Roche, and Sobi. She and/or her institution has received research support from Bayer, Pfizer, Baxter/Shire, and Novo Nordisk. The remaining authors declare no competing financial interests. All unrestricted research grants, awards, educational grants, and consultancy fees have been forwarded to the respective institutions."

"Funding This study was funded by Bayer. L.H.B is funded by the OPTI-CLOT/To-WiN studies and the SYMPHONY consortium. The SYMPHONY consortium aims to orchestrate personalized treatment in people with bleeding disorders, and is a unique collaboration between patients, health care professionals, and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. It aims to identify the best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes, e.g. Diagnostics (workpackage 3 and 4); Treatment (workpackages 5–9), and Fundamental Research (workpackages 10–12). This research received funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M. H. Cnossen; project coordinator: Dr. S. H. Reitsma. Beneficiaries of the SYMPHONY consortium: Erasmus University Medical Center-Sophia Children's Hospital, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., and Swedish Orphan Biovitrum (Belgium) BVBA/SPRL."

" The study was registered in the Dutch Trial register under NTR6769 ( https://trialsearch.who.int/ ). The Medical Ethical Committee approved the study (IRB number: 18–141). Informed consent was obtained from all study participants and data were collected in accordance with the Declaration of Helsinki. "